Ledraxen (Enoxaparin Sodium)

Enoxaparin sodium enhances the activity of antithrombin III, which in turn inhibits factor Xa and, to a lesser extent, factor IIa (thrombin). This blockade reduces the conversion of prothrombin to thrombin, limiting fibrin clot formation and helping to keep blood vessels clear.

The specific dose of Ledraxen is determined by the prescribing clinician based on the patient’s indication, weight, renal function, and other clinical factors. Healthcare professionals calculate the appropriate amount and frequency for each individual case.

Safety data for enoxaparin sodium in pregnancy and lactation are limited. Clinicians must weigh potential benefits against risks, and use the medication only when clearly indicated. Women who are pregnant or nursing should discuss all options with their healthcare provider.

To request Ledraxen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Ledraxen (enoxaparin) is a low molecular weight heparin offering more predictable pharmacokinetics and once‑ or twice‑daily dosing compared with unfractionated heparin, which requires continuous infusion and frequent monitoring. Direct oral anticoagulants provide oral dosing but differ in reversal options and renal clearance considerations.

Ledraxen should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use to maintain stability and sterility.

Ledraxen is given by subcutaneous injection into the abdomen or thigh, or intravenously when rapid anticoagulation is required. Administration technique, injection site rotation, and aseptic handling are performed by trained healthcare professionals.

The most serious risks include major bleeding events such as intracranial hemorrhage, gastrointestinal bleeding, and severe thrombocytopenia (including heparin‑induced thrombocytopenia). Prompt recognition of bleeding signs and regular laboratory monitoring are essential.

Ledraxen is contraindicated in patients with a known hypersensitivity to enoxaparin or other heparins, those with active major bleeding, and individuals with a history of heparin‑induced thrombocytopenia. Clinicians must also assess renal function and avoid use in severe renal impairment without dose adjustment.